Scholarlink

<p>Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating multiple cell cycle checkpoints. Here we characterized the relationship between Cyclin E1/CDK2 activation and sensitivity to the selective WEE1 inhibitor azenosertib. We found that ovarian cancer cell lines with high levels of endogenous Cyclin E1 expression or forced overexpression were exquisitely sensitive to azenosertib and these results extended to in vivo models of ovarian and uterine serous carcinoma. Models with high Cyclin E1 expression showed higher baseline levels of replication stress and enhanced cellular responses to azenosertib treatment. We found azenosertib synergized with different classes of chemotherapy and described distinct underlying mechanisms. Finally, we provided early evidence from an ongoing phase I study demonstrating the clinical activity of monotherapy azenosertib in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月4日

查看全文
  • Daehwan Kim,
  • Heekyung Chung,
  • Wen Liu,
  • Kangjin Jeong,
  • Tugba Y. Ozmen,
  • Furkan Ozmen,
  • Matthew J. Rames,
  • Sangyub Kim,
  • Xiao Guo,
  • Nathan Jameson,
  • Petrus R. de Jong,
  • Steven Yea,
  • Laurie Harford,
  • Jiali Li,
  • Cara A. Mathews,
  • Deborah B. Doroshow,
  • Vincent J. Charles,
  • Doris Kim,
  • Kimberlee Fischer,
  • Ahmed A. Samatar,
  • Adrian Jubb,
  • Kevin D. Bunker,
  • Kimberly Blackwell,
  • Fiona Simpkins,
  • Funda Meric-Bernstam,
  • Gordon B. Mills,
  • Olivier Harismendy,
  • Jianhui Ma,
  • Mark R. Lackner

摘要

Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating multiple cell cycle checkpoints. Here we characterized the relationship between Cyclin E1/CDK2 activation and sensitivity to the selective WEE1 inhibitor azenosertib. We found that ovarian cancer cell lines with high levels of endogenous Cyclin E1 expression or forced overexpression were exquisitely sensitive to azenosertib and these results extended to in vivo models of ovarian and uterine serous carcinoma. Models with high Cyclin E1 expression showed higher baseline levels of replication stress and enhanced cellular responses to azenosertib treatment. We found azenosertib synergized with different classes of chemotherapy and described distinct underlying mechanisms. Finally, we provided early evidence from an ongoing phase I study demonstrating the clinical activity of monotherapy azenosertib in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas.